Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors

Akira Kugaya; Gerard Sanacora; Julie K. Staley; Robert T. Malison; Ali Bozkurt; Shaukat Khan; Amit Anand; Christopher H. Van Dyck; Ronald M. Baldwin; John P. Seibyl; Dennis Charney; Robert B. Innis

doi:10.1016/j.biopsych.2004.07.001

Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors

Akira Kugaya, Gerard Sanacora, Julie K. Staley, Robert T. Malison, Ali Bozkurt, Shaukat Khan, Amit Anand, Christopher H. Van Dyck, Ronald M. Baldwin, John P. Seibyl, Dennis Charney, Robert B. Innis

Research output: Contribution to journal › Article › peer-review

74 Scopus citations

Abstract

Few studies have investigated the predictive value of central serotonin transporter (SERT) availability for treatment response to serotonin reuptake inhibitors (SSRIs). This study used brain imaging to examine the relationship between pretreatment brain SERT availability and transporter occupancy by SSRIs with treatment response in two independent depressed populations. Study 1: Twenty-three patients with major depression underwent a single photon emission computed tomography (SPECT) measurement of brain SERT availability using [ ¹²³I]β-CIT ([¹²³I]methyl 3β-(4-iodophenyl) tropane-2β-carboxylate. The SERT availability was correlated with treatment response to fluoxetine (20 mg/day) assessed with weekly Hamilton Depression Rating Scale (HDRS) for 6 weeks. Study 2: The second group included 10 depressed patients who received 6 weeks of paroxetine treatment (20 mg/day) and serial SPECT scans (baseline, during, and after the treatment). In Study 1, higher pretreatment diencephalic SERT availability significantly predicted better treatment response 4 weeks later. Similar results were found in Study 2 and supported Study 1 findings. The data showed that greater occupancy of diencephalic transporters by paroxetine correlated with better treatment response. Higher pretreatment availability and greater occupancy of SERT in diencephalon may predict better treatment course in response to SSRIs.

Original language	English
Pages (from-to)	497-502
Number of pages	6
Journal	Biological Psychiatry
Volume	56
Issue number	7
DOIs	https://doi.org/10.1016/j.biopsych.2004.07.001
State	Published - 1 Oct 2004
Externally published	Yes

Keywords

Diencephalon
SPECT
SSRI
major depression
serotonin transporter
treatment response

Access to Document

10.1016/j.biopsych.2004.07.001

Cite this

Kugaya, A., Sanacora, G., Staley, J. K., Malison, R. T., Bozkurt, A., Khan, S., Anand, A., Van Dyck, C. H., Baldwin, R. M., Seibyl, J. P., Charney, D., & Innis, R. B. (2004). Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biological Psychiatry, 56(7), 497-502. https://doi.org/10.1016/j.biopsych.2004.07.001

@article{025b4e5e0c9445e4b20fe00dd1d227e0,

title = "Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors",

abstract = "Few studies have investigated the predictive value of central serotonin transporter (SERT) availability for treatment response to serotonin reuptake inhibitors (SSRIs). This study used brain imaging to examine the relationship between pretreatment brain SERT availability and transporter occupancy by SSRIs with treatment response in two independent depressed populations. Study 1: Twenty-three patients with major depression underwent a single photon emission computed tomography (SPECT) measurement of brain SERT availability using [ 123I]β-CIT ([123I]methyl 3β-(4-iodophenyl) tropane-2β-carboxylate. The SERT availability was correlated with treatment response to fluoxetine (20 mg/day) assessed with weekly Hamilton Depression Rating Scale (HDRS) for 6 weeks. Study 2: The second group included 10 depressed patients who received 6 weeks of paroxetine treatment (20 mg/day) and serial SPECT scans (baseline, during, and after the treatment). In Study 1, higher pretreatment diencephalic SERT availability significantly predicted better treatment response 4 weeks later. Similar results were found in Study 2 and supported Study 1 findings. The data showed that greater occupancy of diencephalic transporters by paroxetine correlated with better treatment response. Higher pretreatment availability and greater occupancy of SERT in diencephalon may predict better treatment course in response to SSRIs.",

keywords = "Diencephalon, SPECT, SSRI, major depression, serotonin transporter, treatment response",

author = "Akira Kugaya and Gerard Sanacora and Staley, {Julie K.} and Malison, {Robert T.} and Ali Bozkurt and Shaukat Khan and Amit Anand and {Van Dyck}, {Christopher H.} and Baldwin, {Ronald M.} and Seibyl, {John P.} and Dennis Charney and Innis, {Robert B.}",

note = "Funding Information: This work was supported in part by funds from Eli Lilly; the Department of Veterans Affairs Research Enhancement Award Program Center on Neural Mechanisms and Treatment Response in Depression, at the Veterans Affairs Connecticut Healthcare System, West Haven Campus; a National Alliance for Research on Schizophrenia and Depression Independent Investigator Award (RTM); and Japan Foundation for Aging and Health (PI, S. Yamawaki, Hiroshima University). ",

year = "2004",

month = oct,

day = "1",

doi = "10.1016/j.biopsych.2004.07.001",

language = "English",

volume = "56",

pages = "497--502",

journal = "Biological Psychiatry",

issn = "0006-3223",

publisher = "Elsevier USA",

number = "7",

}

TY - JOUR

T1 - Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors

AU - Kugaya, Akira

AU - Sanacora, Gerard

AU - Staley, Julie K.

AU - Malison, Robert T.

AU - Bozkurt, Ali

AU - Khan, Shaukat

AU - Anand, Amit

AU - Van Dyck, Christopher H.

AU - Baldwin, Ronald M.

AU - Seibyl, John P.

AU - Charney, Dennis

AU - Innis, Robert B.

N1 - Funding Information: This work was supported in part by funds from Eli Lilly; the Department of Veterans Affairs Research Enhancement Award Program Center on Neural Mechanisms and Treatment Response in Depression, at the Veterans Affairs Connecticut Healthcare System, West Haven Campus; a National Alliance for Research on Schizophrenia and Depression Independent Investigator Award (RTM); and Japan Foundation for Aging and Health (PI, S. Yamawaki, Hiroshima University).

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Few studies have investigated the predictive value of central serotonin transporter (SERT) availability for treatment response to serotonin reuptake inhibitors (SSRIs). This study used brain imaging to examine the relationship between pretreatment brain SERT availability and transporter occupancy by SSRIs with treatment response in two independent depressed populations. Study 1: Twenty-three patients with major depression underwent a single photon emission computed tomography (SPECT) measurement of brain SERT availability using [ 123I]β-CIT ([123I]methyl 3β-(4-iodophenyl) tropane-2β-carboxylate. The SERT availability was correlated with treatment response to fluoxetine (20 mg/day) assessed with weekly Hamilton Depression Rating Scale (HDRS) for 6 weeks. Study 2: The second group included 10 depressed patients who received 6 weeks of paroxetine treatment (20 mg/day) and serial SPECT scans (baseline, during, and after the treatment). In Study 1, higher pretreatment diencephalic SERT availability significantly predicted better treatment response 4 weeks later. Similar results were found in Study 2 and supported Study 1 findings. The data showed that greater occupancy of diencephalic transporters by paroxetine correlated with better treatment response. Higher pretreatment availability and greater occupancy of SERT in diencephalon may predict better treatment course in response to SSRIs.

AB - Few studies have investigated the predictive value of central serotonin transporter (SERT) availability for treatment response to serotonin reuptake inhibitors (SSRIs). This study used brain imaging to examine the relationship between pretreatment brain SERT availability and transporter occupancy by SSRIs with treatment response in two independent depressed populations. Study 1: Twenty-three patients with major depression underwent a single photon emission computed tomography (SPECT) measurement of brain SERT availability using [ 123I]β-CIT ([123I]methyl 3β-(4-iodophenyl) tropane-2β-carboxylate. The SERT availability was correlated with treatment response to fluoxetine (20 mg/day) assessed with weekly Hamilton Depression Rating Scale (HDRS) for 6 weeks. Study 2: The second group included 10 depressed patients who received 6 weeks of paroxetine treatment (20 mg/day) and serial SPECT scans (baseline, during, and after the treatment). In Study 1, higher pretreatment diencephalic SERT availability significantly predicted better treatment response 4 weeks later. Similar results were found in Study 2 and supported Study 1 findings. The data showed that greater occupancy of diencephalic transporters by paroxetine correlated with better treatment response. Higher pretreatment availability and greater occupancy of SERT in diencephalon may predict better treatment course in response to SSRIs.

KW - Diencephalon

KW - SPECT

KW - SSRI

KW - major depression

KW - serotonin transporter

KW - treatment response

UR - http://www.scopus.com/inward/record.url?scp=4644363462&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2004.07.001

DO - 10.1016/j.biopsych.2004.07.001

M3 - Article

C2 - 15450785

AN - SCOPUS:4644363462

SN - 0006-3223

VL - 56

SP - 497

EP - 502

JO - Biological Psychiatry

JF - Biological Psychiatry

IS - 7

ER -

Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors

Abstract

Keywords

Access to Document

Fingerprint

Cite this